Literature DB >> 9467850

Genetic changes associated with immortalization. A review.

E L Duncan1, R R Reddel.   

Abstract

Human fibroblasts appear to have three terminal proliferative arrest (TPA) states that act as independent barriers to immortalization. The first of these TPA states is senescence, and several recent studies have shown that abrogation of p53 function permits temporary escape from senescence that ends in a poorly characterized form of arrest (referred to as p53-minus TPA) in which the pRB and p16INK4 genes appear to be involved. Abrogation of the function of both p53 and pRB (or p16INK4) results in continued proliferation until the cells enter crisis. Escape from crisis is always associated with the activation of a telomere maintenance mechanism. We also review evidence for the involvement of other genes in the immortalization process. Immortalization appears to be a complex process involving many genetic changes, not all of which are necessarily related to telomere maintenance.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9467850

Source DB:  PubMed          Journal:  Biochemistry (Mosc)        ISSN: 0006-2979            Impact factor:   2.487


  3 in total

1.  Human papillomavirus type 16 E7 oncoprotein binds and inactivates growth-inhibitory insulin-like growth factor binding protein 3.

Authors:  B Mannhardt; S A Weinzimer; M Wagner; M Fiedler; P Cohen; P Jansen-Dürr; W Zwerschke
Journal:  Mol Cell Biol       Date:  2000-09       Impact factor: 4.272

2.  Insulin-like growth factor-binding protein 3 expression increases during immortalization of cervical keratinocytes by human papillomavirus type 16 E6 and E7 proteins.

Authors:  Allison J Berger; Astrid Baege; Tracy Guillemette; James Deeds; Ron Meyer; Gary Disbrow; Richard Schlegel; Robert Schlegel
Journal:  Am J Pathol       Date:  2002-08       Impact factor: 4.307

3.  Human ovarian surface epithelial cells immortalized with hTERT maintain functional pRb and p53 expression.

Authors:  N F Li; S Broad; Y J Lu; J S Yang; R Watson; T Hagemann; G Wilbanks; I Jacobs; F Balkwill; D Dafou; S A Gayther
Journal:  Cell Prolif       Date:  2007-10       Impact factor: 6.831

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.